Detalhe da pesquisa
1.
CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.
Cancer Res
; 83(24): 4130-4141, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37934115
2.
JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors.
J Med Chem
; 65(24): 16173-16203, 2022 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399068
3.
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
Mol Cancer Ther
; 18(7): 1323-1334, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31068384
4.
Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.
Cancer Res
; 76(2): 390-402, 2016 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26577700
5.
Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.
Mol Cancer Ther
; 11(8): 1747-57, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22653967